Erasca Inc (ERAS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jonathan E. Lim
Employees:
120
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO, CA 92121
(858) 465-6511

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia.

Data derived from most recent annual or quarterly report
Market Cap 492.153 Million Shares Outstanding121.82 Million Avg 30-day Volume 1.006 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.2
Price to Revenue0.0 Debt to Equity0.0 EBITDA-138.231 Million
Price to Book Value2.5792 Operating Margin0.0 Enterprise Value576.73 Million
Current Ratio13.214 EPS Growth0 Quick Ratio12.859
1 Yr BETA 1.3483 52-week High/Low 12.8 / 3.6 Profit Margin0.0
Operating Cash Flow Growth-41.5322 Altman Z-Score5.7588 Free Cash Flow to Firm 0
Earnings Report2023-03-23
View SEC Filings from ERAS instead.

View recent insider trading info

Funds Holding ERAS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ERAS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-09:
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-07:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    765.4 Thousand total shares from 7 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LIM JONATHAN E CHAIRMAN & CEO

    • Officer
    • Director
    • 10% Owner
    32,155,582 2023-01-10 3

    START VALERIE DENISE HARDING

    • Director
    12,000 2022-12-21 2

    BRISTOL JAMES ARTHUR

    • Director
    207,500 2022-12-21 2

    CHEN BIHUA

    CORMORANT ASSET MANAGEMENT, LP

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    CORMORANT PRIVATE HEALTHCARE FUND II, LP

    • Director
    11,019,912 2022-12-20 2

    CASDIN ALEXANDER W.

    • Director
    537,724 2022-12-15 3

    HAMBLETON JULIE

    • Director
    40,000 2022-06-22 1

    MULTANI PRATIK S

    • Director
    40,000 2022-06-22 1

    CHEN BIHUA

    • Director
    10,712,220 2022-06-22 1

    VARNEY MICHAEL DAVID

    • Director
    60,000 2022-06-22 1

    LIU JEAN I

    • Director
    0 2022-04-25 2

    GARNER EBUN GENERAL COUNSEL & CORP. SEC.

    • Officer
    173,000 2022-02-01 1

    CHACKO DAVID M. CHIEF FINANCIAL OFFICER

    • Officer
    603,623 2022-02-01 1

    WEI LIN CHIEF MEDICAL OFFICER

    • Officer
    586,162 2022-02-01 1

    ARCH VENTURE PARTNERS X, LLC

    ARCH VENTURE FUND X, L.P.

    ARCH VENTURE FUND X OVERAGE, L.P.

    ARCH VENTURE PARTNERS X, L.P.

    ARCH VENTURE PARTNERS X OVERAGE, L.P.

    NELSEN ROBERT

    CRANDELL KEITH

    BUROW KRISTINA

    GILLIS STEVEN

    • 10% Owner
    11,055,554 2021-07-20 0

    LIM JONATHAN E SEE REMARKS

    LIM CONYEE T.

    CITY HILL, LLC

    • Officer
    • Director
    • 10% Owner
    32,055,582 2021-07-20 3

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    LIM JONATHAN E - Director - Officer - > 10% Owner CHAIRMAN & CEO by jonathan e. lim and conyee t. lim family trust, dated april 28, 2005

    2023-01-10 16:46:07 -0500 2023-01-10 P 60,000 $3.86 a 20,256,222 indirect 5.679 -5.9259 5.679 2 -5.9259 6

    BRISTOL JAMES ARTHUR - Director by bristol survivor?s trust, dated october 26, 2019

    2022-12-22 21:26:16 -0500 2022-12-21 P 20,000 $4.14 a 20,000 indirect -5.122 3.9024 5.122 5 -5.122 2

    START VALERIE DENISE HARDING - Director by start 2006 trust

    2022-12-22 21:28:43 -0500 2022-12-21 P 10,000 $4.64 a 10,000 indirect -5.122 3.9024 5.122 5 -5.122 2

    CASDIN ALEXANDER W. - Director

    2022-12-15 16:47:21 -0500 2022-12-15 P 20,000 $4.87 a 443,974 direct -2.1978 -9.8901 0.0 1 -9.8901 6

    LIM JONATHAN E - Director - Officer - > 10% Owner CHAIRMAN & CEO by jonathan e. lim and conyee t. lim family trust, dated april 28, 2005

    2022-12-15 11:53:55 -0500 2022-12-14 P 40,000 $4.99 a 20,196,222 indirect -4.6122 -12.1593 0.0 1 -12.1593 6

    CHEN BIHUA - Director see footnotes

    CORMORANT ASSET MANAGEMENT, LP - Director see footnotes

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP - Director see footnotes

    CORMORANT PRIVATE HEALTHCARE FUND II, LP - Director see footnotes

    2022-12-20 17:42:47 -0500 2022-12-13 P 307,692 $6.50 a 10,813,246 indirect -0.2381 -1.9048 0.0 1 -7.381 4

    CHEN BIHUA - Director see footnotes

    CORMORANT ASSET MANAGEMENT, LP - Director see footnotes

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP - Director see footnotes

    CORMORANT PRIVATE HEALTHCARE FUND II, LP - Director see footnotes

    2022-12-21 16:33:57 -0500 2022-12-13 P 307,692 $6.50 a 10,813,246 indirect -2.148 2.864 2.864 6 -7.1599 3

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ERASCA INC ERAS 2023-01-27 22:15:03 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 21:45:04 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 21:15:04 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 20:45:03 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 20:15:04 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 19:45:03 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 19:15:03 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 18:45:04 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 18:15:03 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 17:45:03 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 17:15:04 UTC 3.6056 0.7144 300000
    ERASCA INC ERAS 2023-01-27 16:45:03 UTC 3.6122 0.7078 300000
    ERASCA INC ERAS 2023-01-27 16:15:03 UTC 3.6122 0.7078 300000
    ERASCA INC ERAS 2023-01-27 15:45:03 UTC 3.6122 0.7078 350000
    ERASCA INC ERAS 2023-01-27 15:15:04 UTC 3.6122 0.7078 350000
    ERASCA INC ERAS 2023-01-27 14:45:04 UTC 3.5845 0.7355 300000
    ERASCA INC ERAS 2023-01-27 14:15:03 UTC 3.5845 0.7355 350000
    ERASCA INC ERAS 2023-01-27 13:45:03 UTC 3.6016 0.7184 350000
    ERASCA INC ERAS 2023-01-27 13:15:03 UTC 3.6016 0.7184 300000
    ERASCA INC ERAS 2023-01-27 12:45:03 UTC 3.6016 0.7184 300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ERAS -1800.0 shares, $-14040.0 2022-09-30 N-PORT
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund ERAS -20828.0 shares, $-162458.4 2022-09-30 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund ERAS -1912.0 shares, $-15621.04 2022-10-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments